EUVIMEDEUVIMED entdecken
Crossref

Golden Hour Treatment With tPA (Tissue-Type Plasminogen Activator) in the BEST-MSU Study

Jason Mackey iD, Jose-Miguel Yamal iD, Stephanie A Parker iD, Kelly Silnes iD, Suja S Rajan, Asha P Jacob iD, Mengxi Wang, Noopur Singh iD, William J Jones iD, Ilana Spokoyny iD, Babak B Navi iD, Jeffrey L Saver iD und 2 weitere

Stroke · 2023-02 · 54 (2) · 415-425

DOI: 10.1161/strokeaha.122.039821 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke, 2023-02. Verfasst von Jason Mackey und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Indiana University School of Medicine, Indianapolis (J.M., K.S.). Hauptthemen laut MEDLINE: Ischemic Stroke, Stroke, Brain Ischemia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment of patients with acute ischemic stroke on mobile stroke units (MSUs) improves outcomes compared with management by standard emergency medical services ambulances and is associated with more patients treated with intravenous tPA (tissue-type plasminogen activator) in the first golden hour after last known normal. We explored the predictors and outcomes of first-hour treatment (FHT) compared with later treatment in an alternating-week cluster-controlled trial of MSUs.

Methods

We analyzed all patients treated with intravenous tPA in the BEST-MSU Study (Benefits of Stroke Treatment Delivered by a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services). After stratifying by treatment timeframe, we identified factors associated with FHT. We performed adjusted analyses of the association between FHT and clinical outcome and modeled the shape of the relationship between last known normal–to–treatment time and excellent outcome.

Results

Among 941 tPA-treated patients, 206 (21.8%) had lytic started within 60 minutes. Treatment on the MSU, older age, male sex, alert by 911, faster arrival on-scene and imaging, more severe stroke, atrial fibrillation, and absence of heart failure and pretreatment antihypertensive treatment were associated with FHT. Compared with later treatment, FHT was associated with higher adjusted odds ratio for 90-day modified Rankin Scale score of 0 to 1 (odds ratio, 1.87 [95% CI, 1.25–2.84]; P =0.003). Among FHT patients, 68% achieved a 90-day modified Rankin Scale of 0 or 1 or returned to their baseline status. FHT was not associated with higher risk of hemorrhage and was associated with reduced risk of treating neurovascular mimics.

Conclusions

FHT almost doubles the odds of excellent clinical outcome without increased risk compared with later treatment, which supports the use of MSUs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ischemic StrokeStrokeBrain IschemiaHumansMaleTissue Plasminogen ActivatorTreatment OutcomeAmbulancesThrombolytic TherapyFibrinolytic Agents

Stichwörter der Autor:innen

emergency medical servicesischemic strokeodds ratiopatientstomography

Substanzen

Tissue Plasminogen ActivatorFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Neurology, Indiana University School of Medicine, Indianapolis (J.M., K.S.).
  • Department of Biostatistics and Data Science, University of Texas School of Public Health, Houston (J.-M.Y., S.S.R., M.W., N.S.).
  • Department of Neurology, University of Texas McGovern Medical School, Houston (S.A.P., A.P.J.).
  • University of Buckingham Medical School, United Kingdom (K.S.).
  • Department of Neurology, University of Colorado, Aurora (W.J.J.).
  • Department of Neurology, Mills Peninsula Medical Center, Burlingame, CA (I.S.).

ORCID-Profile: Jason Mackey, Jose-Miguel Yamal, Stephanie A Parker, Kelly Silnes, Asha P Jacob, Noopur Singh, William J Jones, Ilana Spokoyny, Babak B Navi, Jeffrey L Saver, James C Grotta

Zitieren

APA

Mackey, J., Yamal, J. M., Parker, S. A., Silnes, K., Rajan, S. S., Jacob, A. P., Wang, M., Singh, N., Jones, W. J., Spokoyny, I., Navi, B. B., Saver, J. L., Grotta, J. C., & BEST-MSU Study Group (2023). Golden Hour Treatment With tPA (Tissue-Type Plasminogen Activator) in the BEST-MSU Study. Stroke, 54(2), 415-425. https://doi.org/10.1161/strokeaha.122.039821

Vancouver

Mackey J, Yamal JM, Parker SA, Silnes K, Rajan SS, Jacob AP, et al. Golden Hour Treatment With tPA (Tissue-Type Plasminogen Activator) in the BEST-MSU Study. Stroke. 2023;54(2):415-425. doi:10.1161/strokeaha.122.039821

BibTeX
@article{Mackey2023,
  author = {Mackey, Jason and Yamal, Jose-Miguel and Parker, Stephanie A and Silnes, Kelly and Rajan, Suja S and Jacob, Asha P and Wang, Mengxi and Singh, Noopur and Jones, William J and Spokoyny, Ilana and Navi, Babak B and Saver, Jeffrey L and Grotta, James C and BEST-MSU Study Group, BEST-MSU Study Group},
  title = {Golden Hour Treatment With tPA (Tissue-Type Plasminogen Activator) in the BEST-MSU Study},
  journal = {Stroke},
  year = {2023},
  volume = {54},
  number = {2},
  pages = {415--425},
  doi = {10.1161/strokeaha.122.039821}
}
Kostenlos starten →